Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1976 Jan;9(1):11–19. doi: 10.1128/aac.9.1.11

Susceptibility of Beta-Hemolytic Streptococci to 65 Antibacterial Agents

Maxwell Finland *, Carol Garner †, Clare Wilcox †, Leon D Sabath †,1
PMCID: PMC429467  PMID: 176926

Abstract

Tests for susceptibility of 29 group A, 4 group C, and 2 group G strains of beta-hemolytic streptococci to 63 antibiotics and to trimethoprim and sulfamethoxazole, singly and combined in a ratio of 1:16, were carried out in vitro. All strains tested were moderately or highly susceptible to all the antibiotics used except those belonging to the aminoglycoside and polymyxin groups. A few were also resistant to the tetracyclines and to sulfamethoxazole alone. Comparisons with results obtained in previous years indicate that, except for the tetracyclines and sulfonamides, there has been no change in the susceptibility of beta-hemolytic streptococci to the most important and useful antibiotics, particularly penicillin.

Full text

PDF
11

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baker C. J., Barrett F. F. Group B streptococcal infections in infants. The importance of the various serotypes. JAMA. 1974 Nov 25;230(8):1158–1160. [PubMed] [Google Scholar]
  2. Barton L. L., Feigin R. D., Lins R. Group B beta hemolytic streptococcal meningitis in infants. J Pediatr. 1973 Apr;82(4):719–723. doi: 10.1016/s0022-3476(73)80605-5. [DOI] [PubMed] [Google Scholar]
  3. Braun P., Tillotson J. R., Wilcox C., Finland M. Cephalexin and cephaloglycin activity in vitro and absorption and urinary excretion of single oral doses in normal young adults. Appl Microbiol. 1968 Nov;16(11):1684–1694. doi: 10.1128/am.16.11.1684-1694.1968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Braun P., Tillotson J. R., Wilcox C., Finland M. Cephalexin and cephaloglycin activity in vitro and absorption and urinary excretion of single oral doses in normal young adults. Appl Microbiol. 1968 Nov;16(11):1684–1694. doi: 10.1128/am.16.11.1684-1694.1968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. CASBERG M. A. Medical organization in national catastrophe. J Am Med Assoc. 1954 Feb 6;154(6):501–506. [PubMed] [Google Scholar]
  6. EICKHOFF T. C., FINLAND M., WILCOX C. IN VITRO SUSCEPTIBILITY OF GROUP A BETA HEMOLYTIC STREPTOCOCCI TO 18 ANTIBIOTICS. Am J Med Sci. 1965 Mar;249:261–268. doi: 10.1097/00000441-196503000-00002. [DOI] [PubMed] [Google Scholar]
  7. EICKHOFF T. C., KLEIN J. O., DALY A. K., INGALL D., FINLAND M. NEONATAL SEPSIS AND OTHER INFECTIONS DUE TO GROUP B BETA-HEMOLYTIC STREPTOCOCCI. N Engl J Med. 1964 Dec 10;271:1221–1228. doi: 10.1056/NEJM196412102712401. [DOI] [PubMed] [Google Scholar]
  8. FINLAND M., WILCOX C., FRANK P. F. In vitro sensitivity of human pathogenic strains of streptococci to seven antibiotics. Am J Clin Pathol. 1950 Mar;20(3):208–217. doi: 10.1093/ajcp/20.3.208. [DOI] [PubMed] [Google Scholar]
  9. GOCKE T. M., JACKSON G. G., WILCOX C., FINLAND M. In vitro studies on terramycin. Ann N Y Acad Sci. 1950 Sep;53(2):297–302. doi: 10.1111/j.1749-6632.1950.tb42162.x. [DOI] [PubMed] [Google Scholar]
  10. HAIGHT T. H., FINLAND M. The antibacterial action of erythromycin. Proc Soc Exp Biol Med. 1952 Oct;81(1):175–183. doi: 10.3181/00379727-81-19815. [DOI] [PubMed] [Google Scholar]
  11. HIRSCH H. A., FINLAND M. Comparative activity of four tetracycline analogues against pathogenic bacteria in vitro. Am J Med Sci. 1960 Mar;239:288–294. doi: 10.1097/00000441-196003000-00004. [DOI] [PubMed] [Google Scholar]
  12. Howard J. B., McCracken G. H., Jr The spectrum of group B streptococcal infections in infancy. Am J Dis Child. 1974 Dec;128(6):815–818. doi: 10.1001/archpedi.1974.02110310063011. [DOI] [PubMed] [Google Scholar]
  13. JONES W. F., Jr, FELDMAN H. A., FINLAND M. Susceptibility of hemolytic streptococci, other than those of group D, to eleven antibiotics in vitro. Am J Clin Pathol. 1957 Feb;27(2):159–169. doi: 10.1093/ajcp/27.2.159. [DOI] [PubMed] [Google Scholar]
  14. JONES W. F., Jr, FINLAND M. Susceptibility of enterococci and of hemolytic streptococci of groups A, B, C, and G to five new antibiotics in vitro. Am J Clin Pathol. 1957 May;27(5):528–533. doi: 10.1093/ajcp/27.5.528. [DOI] [PubMed] [Google Scholar]
  15. KISLAK J. W., EICKHOFF T. C., FINLAND M. CLOXACILLIN: ACTIVITY IN VITRO, AND ABSORPTION AND URINARY EXCRETION IN NORMAL YOUNG MEN. Am J Med Sci. 1965 Jun;249:636–646. doi: 10.1097/00000441-196506000-00002. [DOI] [PubMed] [Google Scholar]
  16. KLEIN J. O., EICKHOFF T. C., FINLAND M. GENTAMICIN: ACTIVITY IN VITRO AND OBSERVATIONS IN 26 PATIENTS. Am J Med Sci. 1964 Nov;248:528–544. [PubMed] [Google Scholar]
  17. KLEIN J. O., EICKHOFF T. C., TILLES J. G., FINLAND M. CEPHALOTHIN: ACTIVITY IN VITRO, ABSORPTION AND EXCRETION IN NORMAL SUBJECTS AND CLINICAL OBSERVATIONS IN 40 PATIENTS. Am J Med Sci. 1964 Dec;248:640–656. [PubMed] [Google Scholar]
  18. KLEIN J. O., FINLAND M. Ampicillin activity in vitro and absorption and excretion in normal young men. Am J Med Sci. 1963 May;245:544–555. [PubMed] [Google Scholar]
  19. KLEIN J. O., FINLAND M. NAFCILLIN. ANTIBACTERIAL ACTION IN VITRO AND ABSORPTION AND EXCRETION IN NORMAL YOUNG MEN. Am J Med Sci. 1963 Jul;246:10–26. doi: 10.1097/00000441-196307000-00002. [DOI] [PubMed] [Google Scholar]
  20. KUHARIC H. A., ROBERTS C. E., Jr, KIR BY W. M. Tetracycline resistance of group A beta hemolytic streptococci. JAMA. 1960 Dec 3;174:1779–1782. doi: 10.1001/jama.1960.03030140001001. [DOI] [PubMed] [Google Scholar]
  21. MCCARTHY C. G., WALLMARK G., FINLAND M. In vitro activity of various penicillins. Am J Med Sci. 1961 Feb;241:143–159. doi: 10.1097/00000441-196102000-00001. [DOI] [PubMed] [Google Scholar]
  22. MOGABGAB W. J., PELON W. An outbreak of pharyngitis due to tetracyclineresistant group A, type 12 streptococci. AMA J Dis Child. 1958 Dec;96(6):696–698. doi: 10.1001/archpedi.1958.02060060698007. [DOI] [PubMed] [Google Scholar]
  23. McCall C. E., Steigbigel N. H., Finland M. Lincomycin: activity in vitro and absorption and excretion in normal young men. Am J Med Sci. 1967 Aug;254(2):144–155. [PubMed] [Google Scholar]
  24. McGehee R. F., Jr, Smith C. B., Wilcox C., Finland M. Comparative studies of antibacterial activity in vitro and absorption and excretion of lincomycin and clinimycin. Am J Med Sci. 1968 Nov;256(5):279–292. doi: 10.1097/00000441-196811000-00002. [DOI] [PubMed] [Google Scholar]
  25. McGowan J. E., Jr, Barnes M. W., Finland M. Bacteremia at Boston City Hospital: Occurrence and mortality during 12 selected years (1935-1972), with special reference to hospital-acquired cases. J Infect Dis. 1975 Sep;132(3):316–335. doi: 10.1093/infdis/132.3.316. [DOI] [PubMed] [Google Scholar]
  26. STILLERMAN M., BERNSTEIN S. H., SMITH M. L., GITTELSON S. B., KARELITZ S. Antibotics in the treatment of betahemolytic streptococcal pharyngitis: factors influencing the results. Pediatrics. 1960 Jan;25:27–34. [PubMed] [Google Scholar]
  27. Sabath L. D., Wilcox C., Garner C., Finland M. In vitro activity of cefazolin against recent clinical bacterial isolates. J Infect Dis. 1973 Oct;128(Suppl):S320–S326. doi: 10.1093/infdis/128.supplement_2.s320. [DOI] [PubMed] [Google Scholar]
  28. Steigbigel N. H., Reed C. W., Finland M. Susceptibility of common pathogenic bacteria to seven tetracycline antibiotics in vitro. Am J Med Sci. 1968 Mar;255:179–195. doi: 10.1097/00000441-196803000-00005. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES